Health Impacts of Chronic Radiation Exposure in Northern Kazakhstan: A Comprehensive Epidemiological Review

2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3390/cancers18091404
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Chronic exposure to ionizing radiation from uranium legacy sites remains a significant public health concern in Northern Kazakhstan. This review evaluates epidemiological, clinical, and environmental evidence published between 2000 and 2025, with particular emphasis on studies conducted during 2014–2023 in the Stepnogorsk region among populations residing near former uranium mining sites. Residents were exposed to annual external gamma doses of approximately 1.0–3.5 mSv and radon-related doses of up to 1.2 mSv. Cancer registry analyses revealed 1913 malignancy cases in the exposed group (vs. 358 controls), with digestive (29%) and respiratory (17%) cancers predominating. Early signs of chronic radiation syndrome (CRS) were consistently observed, including olfactory dysfunction, immunosuppression, vestibular disturbances, hematologic anomalies, and elevated chromosomal aberrations (1.3–1.5× baseline). Non-cancer morbidity was also elevated, including hypertension (32% vs. 24%), chronic bronchitis (14% vs. 8%), and reduced forced expiratory volume in one second (FEV1; −9.7%), indicating broader systemic effects. These results underscore the need for targeted public health strategies incorporating CRS biomarker screening, cancer surveillance, personal dosimetry, and environmental remediation in uranium-impacted communities.